The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study
文献类型：期刊论文
| 作者 | Yang, Haiyan1,2; Li, Cong1,2 |
| 刊名 | BLOOD
 |
| 出版日期 | 2021-11-23 |
| 卷号 | 138 |
| ISSN号 | 0006-4971 |
| DOI | 10.1182/blood-2021-149541 |
| WOS研究方向 | Hematology |
| 语种 | 英语 |
| WOS记录号 | WOS:000736413901211 |
| 出版者 | AMER SOC HEMATOLOGY |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/131938]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Chinese Acad Sci, Inst Canc & Basic Med IBMC, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yang, Haiyan,Li, Cong. The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study[J]. BLOOD,2021,138. |
| APA | Yang, Haiyan,&Li, Cong.(2021).The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study.BLOOD,138. |
| MLA | Yang, Haiyan,et al."The Combination of Bortezomib with Cyclophosphamide, Epirubicin, Etoposide and Prednisone (BCHEP) Regimen As First-Line Treatment for Untreated Patients with Peripheral T Cell Lymphoma: A Prospective, Single Arm, Phase II Study".BLOOD 138(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。